Celgene to Present at the Cancer Diagnosis & Therapy Congress to be Held in London

KIDLINGTON, England, April 23, 2015 /PRNewswire/ --

Prof. Stefan Gluck - Vice President, Global Medical Affairs; Breast, Ovarian Cancer, Immunotherapy at Celgene - USA will be presenting on Immuno-Oncology: New Developments in Solid Tumor therapy at the Cancer Diagnosis and Therapy Congress that will be held on 3 - 4 September, 2015 in London, UK. He will focus on topics such as impact of MoA on solid tumours, check point regulation and understanding roles of Tregs among others.

Register for the Event: http://www.mnmconferences.com/cancer-diagnosis-therapy-congress.html

Early Bird Discounts Available: Register before May, Use WM/CDT/10 as your Discount Code

Talking about the latest developments in solid tumor therapy, Prof. Gluck said, "Solid Tumor Systemic Therapy was dominated over several decades by cytotoxic chemotherapy. Only few selected tumours were treated with targeted therapy e.g., anti-hormone approaches if estrogen receptor was identified as a biological target and later on with human epidermal growth factor receptors as targets. Only occasionally immunotherapy in the form of vaccination was available. Recently, through better molecular understanding of the immune system, immuno therapy has begun to emerge and now there are several compounds in the market." He further added, "These treatments helped in two ways to improve outcome in some selected solid tumours; prolonging effect of treatment including survival and reducing or avoiding toxicity of cytotoxic therapy."

Other speakers at the congress are representing organizations such as Agenus & 4-Antibody AG - Switzerland, European Society of Surgical Oncologists - UK, Imperial College London - UK, Wolfgang Goethe-University - Germany, Queen's University Belfast - UK, University of Leicester - UK, The British Association for Cancer Research - UK, APeX Disease Research Institute - USA, Valdarno Hospital - Italy, Foundation for Collaborative Medicine and Research - USA, University of Buenos Aires - Argentina, British Association of Surgical Oncology - UK & Nanomerics Ltd - UK.

Bringing together more than 150 experts from industry, research laboratories, hospitals, device and diagnostic manufacturers and academia in the arena of cancer research, the congress will be an excellent opportunity to meet and network with industry peers and share experiences.

The Two Day Congress will cover topics such as integration of irreversible electroporation with chemotherapy in the treatment of locally advanced pancreatic carcinoma, NGS and bioinformatics for cancer immunotherapies, electrochemical biosensors for prostate cancer diagnosis, bio banking international harmonization and globalization and the role of protein homeostasis in the genesis of cancer.

The Full Agenda can be downloaded from the Event Website:

http://www.mnmconferences.com/cancer-diagnosis-therapy-congress_agenda.html

About MnM Conferences  

MarketsandMarkets Conferences (MnM Conferences) produces global summits, congresses and conferences bringing together key industry experts from academia and industry sharing and exchanging ideas and latest research through cutting edge conference programs and interactive panel and round table discussions. Conferences are currently held or planned in the UK, Europe, USA and across Asia.

Industry suppliers have the opportunity to showcase their products and services to senior level decision makers as well as unparalleled marketing and branding opportunities to maximise ROI and onsite exposure.

MnM Conferences is a wholly owned division of MarketsandMarkets, a global market research company established in 2009.

Contact
Mr. Steve Hambrook   

The Kidlington Centre
Kidlington, Oxfordshire
OX5 2DL
United Kingdom
Tel: +44 (0)1865-842-976

Email: [email protected]
Visit: http://www.mnmconferences.com/
Connect with us on Linkedin: https://www.linkedin.com/company/mnm-conferences

SOURCE mnmconferences.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED